Paul A. Grayson has served as a member of our board of directors since November 2018. Mr. Grayson currently serves as the President and Chief Executive Officer of Tentarix Biotherapeutics Inc. Mr. Grayson formally served as a Venture Partner at Versant Venture Management LLC, a life science venture capital firm investing in early-stage healthcare companies, since June 2018. Mr. Grayson has also served as the Chief Executive Officer of Bird Rock Bio Inc. since June 2011 and on the board of directors of Tempest Therapeutics since November 2018. Mr. Grayson also served as the founding Chief Executive Officer of Fate Therapeutics, Inc. (NASDAQ: FATE) from 2008 to 2011, as the managing director of Sanderling Ventures from 2003 to 2008 and as the founding Chairman and Chief Executive Officer of Senomyx Inc. from 1999 to 2003. Mr. Grayson received a B.S. in Biochemistry and Computer Science from the University of California, Los Angeles in 1987 and an M.B.A. from the Paul Merage School of Business at the University of California, Irvine in 1991.